ArticleClinical case reports2025
Aortobronchial Fistula: A Case Report and Literature Review.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aortobronchial Fistula: A Case Report and Literature Review.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This report details the urgent management of a life-threatening aortobronchial fistula (ABF) in a 61-year-old male with a history of esophageal cancer surgery, who presented with massive hemoptysis, underscoring the critical role of rapid diagnosis and endovascular intervention in this rare vascular complication. Emergency digital subtraction angiography (DSA) confirmed the ABF, prompting immediate thoracic endovascular aortic repair (TEVAR) with successful deployment of a stent graft, which achieved complete hemostasis, restored aortic integrity, and resulted in an uncomplicated postoperative course without recurrent bleeding. The case reinforces TEVAR as a minimally invasive and definitive therapeutic strategy for ABF, particularly in high-risk surgical candidates, while highlighting the indispensable role of angiographic imaging in acute settings and the need for heightened clinical suspicion in patients with prior thoracic interventions to avert catastrophic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.